| Literature DB >> 34206211 |
Marwa Reda Bakkar1, Ahmed Hassan Ibrahim Faraag1,2, Elham R S Soliman3, Manar S Fouda4, Amir Mahfouz Mokhtar Sarguos5, Gary R McLean6,7, Ali M S Hebishy8, Gehad E Elkhouly9,10, Nermeen R Raya9,10, Yasmin Abo-Zeid9,10.
Abstract
COVID-19 is a pandemic disease caused by the SARS-CoV-2, which continues to cause global health and economic problems since emerging in China in late 2019. Until now, there are no standard antiviral treatments. Thus, several strategies were adopted to minimize virus transmission, such as social distancing, face covering protection and hand hygiene. Rhamnolipids are glycolipids produced formally by Pseudomonas aeruginosa and as biosurfactants, they were shown to have broad antimicrobial activity. In this study, we investigated the antimicrobial activity of rhamnolipids against selected multidrug resistant bacteria and SARS-CoV-2. Rhamnolipids were produced by growing Pseudomonas aeruginosa strain LeS3 in a new medium formulated from chicken carcass soup. The isolated rhamnolipids were characterized for their molecular composition, formulated into nano-micelles, and the antibacterial activity of the nano-micelles was demonstrated in vitro against both Gram-negative and Gram-positive drug resistant bacteria. In silico studies docking rhamnolipids to structural and non-structural proteins of SARS-CoV-2 was also performed. We demonstrated the efficient and specific interaction of rhamnolipids with the active sites of these proteins. Additionally, the computational studies suggested that rhamnolipids have membrane permeability activity. Thus, the obtained results indicate that SARS-CoV-2 could be another target of rhamnolipids and could find utility in the fight against COVID-19, a future perspective to be considered.Entities:
Keywords: COVID-19; Pseudomonas aeruginosa; SARS-CoV-2; antibacterial agent; antiviral agent; docking studies; nano-micelles; rhamnolipids
Year: 2021 PMID: 34206211 PMCID: PMC8300634 DOI: 10.3390/antibiotics10070751
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1Chemical structure of (A) rhamnolipids R1 (mono-rhamnolipids; Rha(s)1) and (B) rhamnolipids R2 (di-rhamnolipids; Rha(s)2). Chemical structures were retrieved from PubChem; https://pubchem.ncbi.nlm.nih.gov (accessed on 16 June 2021).
Congeners composition of rhamnolipids mixture produced by P. aeruginosa strain LeS3 as analyzed by LC/ESI-MS at both positive and negative modes.
| Rha(s) Congeners |
| |||||||
|---|---|---|---|---|---|---|---|---|
| Mol f | Mol wt | [M-H]− | [M+H]+ | [M+Na]+ | [M+K]+ | [M-H+Na2]+ | % Abundance | |
|
| ||||||||
|
| C14H26O7 | 306 | 351 | 12.8 | ||||
|
| C14H24O7 | 304 | 327 | 25.2 | ||||
|
| C14H22O7 | 302 | 325 | 29.4 | ||||
|
| C15H26O7 | 318 | 341 | 0.3 | ||||
|
| C16H30O7 | 334 | 357 | 379 | 13.6 | |||
|
| C16H26O7 | 330 | 353 | 0.12 | ||||
|
| C18H34O7 | 362 | 385 | 0.24 | ||||
|
| C18H30O7 | 358 | 359 | 381 | 2.28 | |||
|
| C19H36O7 | 376 | 421 | 0.56 | ||||
|
| C19H32O7 | 372 | 395 | 0.8 | ||||
|
| C20H38O7 | 390 | 413 | 0.06 | ||||
|
| C21H40O7 | 404 | 443 | 0.24 | ||||
|
| C26H48O9 | 504 | 503 | 527 | 543 | 6.8 | ||
|
| C28H52O9 | 532 | 531 | 577 | 0.52 | |||
|
| C28H50O9 | 530 | 553 | 0.6 | ||||
|
| C33H62O9 | 602 | 603 | 641 | 0.52 | |||
|
| C36H64O9 | 640 | 641 | 0.8 | ||||
|
| ||||||||
|
| C24H42O11 | 506 | 551 | 0.22 | ||||
|
| C28H50O11 | 562 | 601 | 0.62 | ||||
|
| C30H50O13 | 618 | 641 | 657 | 1.42 | |||
|
| C32H58O13 | 650 | 649 | 673 | 1.6 | |||
|
| C44H78O13 | 815 | 816 | 0.03 | ||||
|
| ||||||||
Characterization of Rha(s) nano-micelles prepared at different concentrations; 1, 5 and 10 mg mL−1 in PBS buffer.
| Concentrations of Rhamnolipids | Particle Size | Polydispersity Index | Zeta Potential |
|---|---|---|---|
| 1 | 274 ± 50 | 0.55 | −50.4 ± 1.7 |
| 5 | 164 ± 1 | 0.30 | −62.07 ± 3.8 |
| 10 | 169 ± 10 | 0.27 | −66.77 ± 2.62 |
Figure 2TEM image of rhamnolipids nano-micelles prepared at a concentration of 5 mg mL−1.
The antimicrobial activity of rhamnolipids nano-micelles was presented as average ± standard deviation. Results are average of two independent experiments with three replicates in each.
| Bacterial Strain | Concentration of Rha(s) (mg mL−1) | |||
|---|---|---|---|---|
| MIC | 1 | 5 | 10 | |
| Corresponding Zone of Inhibition (mm) ± SD | ||||
|
| ||||
|
| 0.031 | 9.6 ± 1.2 | 16.5 ± 1 | 23 ± 2 |
|
| 0.031 | 17.8 ± 0.76 | 25 ± 1 | 30 ± 1.5 |
|
| ||||
| >0.5 | 7.1 ± 1 | 15 ± 1 | 21 ± 1.5 | |
| >0.5 | 6.8 ± 0.76 | 12.1 ± 1.2 | 18.1 ± 1.7 | |
Figure 3In silico docking study revealing the interactions between (A) Rha(s)1 and (B) Rha(s)2 with spike glycoproteins (S1-N-terminal domain (NTD) and S2 part) of SARS-CoV-2. PDB accession number for spike glycoproteins is 7CWU.
The docking interaction parameters of both Rha(s)1 and Rha(s)2 with spike glycoproteins of SARS-CoV-2 and enzymes involved in viral replication: EndoRNAse, helicase, RNA-dependent RNA polymerase and protease.
| Ligands | Binding Free Energy | Total Intermolecular | Interacting Amino Acids | Hydrogen Bonds |
|---|---|---|---|---|
|
| ||||
|
| −45 | 14.7 | Gln 52 and Thr 739 | 3H bonds |
|
| −44.6 | 11.8 | Gly 757 | 1H bonds |
|
| ||||
|
| −61 | 20.5 | Glu 41, Glu 44 and Glu 266 | 5H bonds |
|
| −53.9 | 11.5 | Asp, Glu44, and Lys 46 | 4H bonds |
|
| ||||
|
| −66.4 | 14.2 | Gln 537, Glu 375, and Lys 288 | 3H bonds |
|
| −35.5 | 5.7 | Asp542, Glu 540, and Lys 508 | 4H bonds |
|
| ||||
|
| −62.1 | 17.3 | Arg 555, Arg 624, Asp 618, Thr 556 and Lys 621 | 7H bonds |
|
| −55.8 | 13.7 | Arg 555, Arg 624, Asp 618, Thr 556, Arg 553, and Lys 621 | 6H bonds |
|
| ||||
|
| −77 | 22.1 | Glu 288, Glu 290, Leu 282 and Lys 5 | 7H bonds |
|
| −61.1 | 12.1 | Glu 288, Glu 290, Gly 283 and Lys 5 | 6H bonds |
Figure 4In silico docking study revealing interactions between (A) Rha(s)1 and (B) Rha(s)2 with the active sites of SARS-CoV-2 EndoRNAse. PDB accession number for EndoRNAse is 6X1B.
Figure 5In silico docking study revealing interactions between (A) Rha(s)1 and (B) Rha(s)2 with the active sites of SARS-CoV-2 Helicase. PDB accession number for helicase is 5RL6.
Figure 6In silico docking study revealing interactions between (A) Rha(s)1 and (B) Rha(s)2 with the active sites of SARS-CoV-2 RNA-dependent RNA polymerase. PDB accession number for RNA-dependent RNA polymerase is 7CYQ.
Figure 7In silico docking study revealing interactions between (A) Rha(s)1 and (B) Rha(s)2 with the active sites of SARS-CoV2 main protease. PDB accession number for main protease is 6Y2G.
Computational membrane permeability of rhamnolipids (Rha(s)).
| Ligand | Membrane Permeability Prediction | |||||
|---|---|---|---|---|---|---|
| 1 Membrane *dG Insert | 2 Membrane HDLD | 3 Membrane GB | 4 Membrane State Penalty | 5 Log Perm RRCK (cm/s) | Membrane Energy | |
|
| 9.909 | 5.516 | −3.033 | 9.909 | −5.854 | 13.416 |
|
| 6.004 | 1.610 | −6.789 | 6.004 | −5.466 | −1.146 |
* Partition energy “dG” Insert prediction; 1 Membrane dG Insert: the total free energy penalty for the ligand to change state and enter the membrane. This is the net of the energy of Membrane HDLD and Membrane State Penalty; 2 Membrane HDLD: the free energy penalty for the neutral form of the ligand in its conformation inside the membrane to enter the membrane (i.e., move from the high dielectric region to the low dielectric region, hence HDLD). 3 Membrane GB: an implicit membrane generalized born theory model closely reproduces the Poisson–Boltzmann (PB) electrostatic solvation energy profile across the membrane. 4 Membrane State Penalty: a tautomerization penalty is derived from possible tautomer states and their estimated relative populations. These two processes are combined as a state penalty, ΔG state, that represents the free energy cost for the permeant to adopt a particular neutral, tautomeric form for membrane permeation. 5 Log Perm RRCK: logarithm of the RRCK permeability in cm/s. This property is optimized to reproduce RRCK permeability assay results, with fitted energy.
Figure 8Sketch presenting the damage effect caused by rhamnolipids on the lipid bilayer of virus envelope and spike glycoproteins.
Figure 9Sketch presenting the inactivation of SARS-CoV-2 by biosurfactants as a single molecules and nano-micelles.